773 completed, 320 recruiting, 278 unknown, 184 terminated. 572 Phase 2, 391 Phase 1, 389 Not applicable, 191 Phase 3, 35 Phase 4.
Follow Urinary Bladder Neoplasms: new trials by email Literature Review of Urinary Bladder Neoplasms trials Research Report on Urinary Bladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer AI Uro-Cam - Bladder Cancer | Not applicable | Not yet recruiting | Chinese University of Hong Kong | 60 | 2028-07-01 | 2026-10-28 |
| Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC) This is a non-interventional, observational, prospective study. - NMIBC, MIBC | Not yet recruiting | Bladder Cancer Advocacy Network | 1400 | 2027-03-01 | 2026-10-26 | |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 49 | 2027-01-15 | 2026-10-14 |
| Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC. Hyperthermic intravesical chemotherapy (HIVEC) - Non-muscle Invasive Bladder Cancer (NMIBC) | Not applicable | Not yet recruiting | Eight Medical International BV | 30 | 2027-01-01 | 2026-08-14 |
| VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors Low Intensity Surveillance, High Intensity Surveillance - High-Grade Early-Stage Bladder Cancer | Not applicable | Not yet recruiting | VA Office of Research and Development | 2482 | 2027-01-01 | 2026-02-13 |
| Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) ATO-101™ - Bladder Cancer | Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 24 | 2027-01-01 | 2026-06-08 |
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2027-01-01 | 2026-11-05 |
| Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial Electronic Health Record Review, Patient Navigation, Prescreen - Bladder Carcinoma, Prostate Carcinoma | Not applicable | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2027-01-01 | 2026-11-06 |
| The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC ERBT and Adjuvant MMC Therapy, ERBT - Bladder Cancer | Not applicable | Not yet recruiting | Chinese University of Hong Kong | 440 | 2027-01-01 | 2026-10-30 |
| A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer Vepugratinib - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 161 | 2026-12-01 | 2026-10-08 |
| Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | University of Florida | 39 | 2026-12-01 | 2026-09-14 |
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| EHR Integrated Remote Patient Monitoring to Reduce Readmission for Patients With Bladder Cancer Undergoing Cystectomy Best Practice, Communication Intervention, Interview - Bladder Carcinoma | Not applicable | Not yet recruiting | University of Michigan Rogel Cancer Center | 50 | 2026-12-01 | 2026-11-03 |
| Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer Transurethral Resection of Bladder Tumor, Sequential Systemic Chemotherapy, radiotherapy - Bladder Cancer, TURBT | Phase 3 | Not yet recruiting | Assiut University | 71 | 2026-12-01 | 2026-11-03 |
| Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer Radiochemotherapy, Radical cystectomy - Muscle Invasive Bladder Cancer | Not applicable | Not yet recruiting | Brazilian Clinical Research Institute | 336 | 2026-12-01 | 2026-10-29 |
Showing 20 of 1872. Sign in to see all of them.
Non-Muscle Invasive Bladder Neoplasms (286) · Carcinoma, Transitional Cell (209) · Prostatic Neoplasms (193) · Neoplasms (168) · Breast Neoplasms (167) · Lung Neoplasms (156) · Ovarian Neoplasms (154) · Carcinoma, Non-Small-Cell Lung (153) · Stomach Neoplasms (144) · Pancreatic Neoplasms (136) · Colorectal Neoplasms (131) · Esophageal Neoplasms (118) · Uterine Cervical Neoplasms (116) · Carcinoma, Renal Cell (115)
Female Urogenital Diseases and Pregnancy Complications (1871) · Female Urogenital Diseases (1870) · Male Urogenital Diseases (1870) · Urogenital Diseases (1869) · Neoplasms by Site (1859) · Urologic Diseases (1850) · Urogenital Neoplasms (1844) · Urinary Bladder Diseases (1842) · Urologic Neoplasms (1826) · Neoplasms (1704) · Neoplasms by Histologic Type (728) · Neoplasms, Glandular and Epithelial (679) · Carcinoma (654) · Genital Diseases (331) · Digestive System Diseases (290)
Gemcitabine (182) · Cisplatin (120) · pembrolizumab (93) · Mitomycin (56) · Cystectomy (48) · Docetaxel (45) · Carboplatin (44) · Nivolumab (43) · Paclitaxel (41) · Radiotherapy (37) · Magnetic Resonance Spectroscopy (35) · BCG Vaccine (34) · atezolizumab (33) · durvalumab (33) · enfortumab vedotin (29)
National Cancer Institute (NCI) (66) · Memorial Sloan Kettering Cancer Center (50) · M.D. Anderson Cancer Center (31) · Mansoura University (31) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (21) · Assiut University (19) · AstraZeneca (19) · Merck Sharp & Dohme LLC (18) · Eli Lilly and Company (16) · Pfizer (16) · UNC Lineberger Comprehensive Cancer Center (15) · University of Kansas Medical Center (15) · European Organisation for Research and Treatment of Cancer - EORTC (14) · SWOG Cancer Research Network (14) · Janssen Research & Development, LLC (12)
United States (903) · China (209) · France (162) · Canada (158) · United Kingdom (146) · Italy (145) · Spain (142) · South Korea (102) · Germany (94) · Australia (91) · Netherlands (87) · Denmark (77) · Belgium (70) · Egypt (66) · Israel (63)
Ahmed Mosbah, MD (7) · Andrea B Apolo, M.D. (7) · Dean Bajorin, MD (7) · Dean F. Bajorin, MD (7) · Amr A Elsawy (6) · Jian Huang, MD (6) · Yair Lotan, MD (5) · Ali Kaan Yildiz (4) · Arlene Siefker-Radtke, MD (4)
PMID 34125951, PMID 38045238, PMID 38167321, PMID 16389183, PMID 27939400, PMID 29562804, PMID 11001674, PMID 12118019, PMID 17340590, PMID 17409436, PMID 17452976, PMID 19097774, PMID 19687335, PMID 19949018, PMID 20850152, PMID 21831711, PMID 22002018, PMID 22280855, PMID 22512481, PMID 22877502, PMID 23982601, PMID 24373477, PMID 25150172, PMID 25366678, PMID 25428503, PMID 25651787, PMID 26454620, PMID 26952546, PMID 27324428, PMID 27345655, PMID 28453896, PMID 29141603, PMID 29203268, PMID 29489427, PMID 29801011, PMID 30807645, PMID 31395089, PMID 32360052, PMID 33241650, PMID 33408185, PMID 33539743, PMID 34008425, PMID 34051177, PMID 34511303, PMID 35031545, PMID 35247908, PMID 36494006, PMID 37414705, PMID 37496366, PMID 38142702
2023 (24), 2017 (18), 2019 (13), 2014 (10), 2018 (10), U10CA032102 (10), P30CA015704 (7), 2016 (6), 2015 (5), 2025 (5), P30CA014089 (5), P50CA091846 (5), U10CA031946 (5), 2009 (4), P30CA138292 (4)